RNA, U1 small nuclear 75, pseudogeneGenealiases: []
Q-omics provides the consensus-scored RNU1-75P profile across patient tissues and cancer cell-line models. RNU1-75P expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in CHOL. Among the 18 cancer types available for tumor–normal comparison, RNU1-75P is differentially expressed in 7, with the highest sampling consensus in LIHC. Additionally, RNU1-75P RNA expression shows 7,500 significant gene co-expression associations, with the highest sampling consensus in LGG. Together, these results highlight CHOL, LIHC, and LGG as cancer lineages where RNU1-75P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNU1-75P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNU1-75P survival associations across molecular data types. RNU1-75P RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNU1-75P RNA expression–survival associations across cancer types. High RNU1-75P expression shows unfavorable associations in CHOL, KICH, LGG and ACC, but favorable associations in BLCA and LUAD. The CHOL Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify CHOL as the clearest survival context for RNU1-75P RNA expression.
This table summarizes RNU1-75P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for RNU1-75P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNU1-75P shows lower tumor expression in LIHC, KICH, THCA, KIRP, CHOL and PRAD. The LIHC box plot shows higher RNU1-75P RNA expression in normal versus tumor tissue (log2 FC = −1.503, t-test p < 0.001).
This table shows molecular features associated with RNU1-75P in patient tissues and cancer cell lines. In patient samples, RNU1-75P shows the broadest associations at the RNA and protein expression levels, with LGG recurring as the lineage with the largest associated feature set.
